Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up

Braveheart Bio is targeting a valuation of up to $1.2 billion in its planned U.S. initial public offering, according to Reuters, as the San Francisco clinical-stage biopharmaceutical company seeks public capital for its lead hypertrophic cardiomyopathy drug candidate. The company plans to offer 18.8 million shares at a price range of $15 to $17 each, raising as much as $318.8 million at the top end of the range. Braveheart Bio intends to list on the Nasdaq Global Market under the ticker symbol BRVE, with Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor acting as joint bookrunners. Fidelity Management & Research has indicated interest in buying up to $75 million of shares at the IPO price, giving the offering a significant cornerstone signal. The strategic question is whether public investors will reward a fast-moving cardiovascular biotech with encouraging Phase 2 data, or apply a sharper discount because Braveheart Bio remains pre-commercial and faces established competition from Bristol Myers Squibb and Cytokinetics.

Braveheart Bio was founded in 2024 and has already raised about $185 million in Series A financing from investors including Andreessen Horowitz, Forbion and OrbiMed. The company’s lead programme, BHB-1893, also known as HRS-1893, is an oral cardiac myosin inhibitor being developed for obstructive and non-obstructive hypertrophic cardiomyopathy.

The IPO arrives during a more constructive period for biotech listings. After a difficult stretch for early-stage life-sciences companies, investors have become more open to selected clinical-stage IPOs, especially where the asset targets a defined disease area, has human efficacy data and sits in a category where commercial precedent already exists.

Why does Braveheart Bio’s planned IPO matter to the biotech listing market?

Braveheart Bio’s planned IPO matters because it sits at the intersection of two important market tests. The first is whether biotech IPO demand has recovered enough to support clinical-stage companies that still face years of development risk. The second is whether investors are willing to fund challengers in therapeutic categories where the first commercial wave has already begun.

Hypertrophic cardiomyopathy is no longer an untouched market. Bristol Myers Squibb has already commercialised Camzyos for obstructive hypertrophic cardiomyopathy, while Cytokinetics has brought aficamten to market under the Myqorzo brand in obstructive disease and has also generated positive late-stage data in non-obstructive disease. That means Braveheart Bio is not asking investors to believe in the entire mechanism from scratch.

This can help the IPO. Established therapeutic validation reduces some biology risk, because cardiac myosin inhibition has already shown clinical and commercial relevance. Investors can understand the target market, physician community, endpoints and competitive context more clearly than they could with a completely novel mechanism.

However, validation also brings competition. Braveheart Bio must prove that BHB-1893 can offer differentiated efficacy, safety, dosing, convenience, patient reach or label breadth. A me-too profile will not be enough if established brands already control physician attention, payer relationships and regulatory experience.

The IPO therefore is not only a capital raise. It is a public-market judgment on whether there is room for another meaningful player in the HCM treatment landscape.

How is Braveheart Bio structuring the IPO and what does Fidelity’s interest signal?

Braveheart Bio plans to sell 18.8 million shares in the IPO at $15 to $17 each. At the top end of the range, gross proceeds would reach about $318.8 million before underwriting discounts and offering expenses.

The company intends to use proceeds to advance BHB-1893, fund research and development, and support general corporate purposes. That is a standard use of proceeds for a clinical-stage biotechnology company, but the scale of the raise would give Braveheart Bio a larger balance sheet than many newly listed biotechs.

Fidelity Management & Research’s indicated interest in purchasing up to $75 million of shares at the IPO price is important because cornerstone demand can reduce perceived execution risk for an offering. It signals that at least one major institutional investor is willing to underwrite a meaningful portion of the float.

That does not guarantee aftermarket performance. Indications of interest are not binding in the same way as completed purchases, and public investors still need to assess valuation, trial timelines, dilution risk and competition. But the signal is helpful in a market where weak cornerstone support can make biotech IPOs harder to price.

The offering also includes a strong underwriting group. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor give the IPO access to healthcare-specialist investors and broader growth-equity demand.

The key issue is whether the deal prices at the top of the range, the midpoint or below range. Pricing near $17 would show stronger confidence in the story. Pricing lower would suggest investors want a wider risk discount before buying into a pre-commercial HCM challenger.

What is BHB-1893 and why is hypertrophic cardiomyopathy an attractive target?

BHB-1893 is Braveheart Bio’s lead oral cardiac myosin inhibitor candidate. The drug is designed to treat hypertrophic cardiomyopathy, a disease in which the heart muscle becomes abnormally thickened and can impair the heart’s ability to pump or fill properly.

Hypertrophic cardiomyopathy can be classified broadly into obstructive and non-obstructive forms. In obstructive disease, thickened heart muscle can block blood flow out of the heart. In non-obstructive disease, patients may still suffer symptoms and disease progression even without the same outflow obstruction.

Cardiac myosin inhibitors are designed to reduce excessive cardiac contractility and improve cardiac function in selected patients. The therapeutic category has become commercially important because it targets disease biology rather than only treating symptoms.

Braveheart Bio’s May 2026 Phase 2 data with HRS-1893 in non-obstructive hypertrophic cardiomyopathy suggested potential benefit, according to the company and its partner Hengrui Pharma. Those data help support the IPO narrative because non-obstructive HCM remains an area of substantial unmet need and has been harder to address than obstructive disease.

The market opportunity is attractive because HCM is chronic, specialised and clinically serious. Drugs that improve symptoms, functional capacity and disease markers can potentially command meaningful pricing if supported by strong clinical evidence and regulatory approval.

The challenge is that HCM patients require careful monitoring. Cardiac myosin inhibitors can affect heart function, and regulators, physicians and payers will scrutinise safety closely. Braveheart Bio must show that BHB-1893 can deliver benefit without creating unacceptable monitoring or safety burdens.

How does Braveheart Bio compare with Bristol Myers Squibb and Cytokinetics?

Bristol Myers Squibb is the established incumbent through Camzyos, its mavacamten therapy for symptomatic obstructive hypertrophic cardiomyopathy. Bristol Myers Squibb shares recently traded at $65.31, giving the company a market capitalisation of about $133.4 billion.

For Bristol Myers Squibb, Camzyos is one product within a large portfolio. For Braveheart Bio, BHB-1893 is the centre of the company. That creates a very different risk profile. A large pharma company can absorb trial setbacks or payer pressure more easily than a young biotech built around one lead asset.

Cytokinetics is the more directly comparable public biotech because its aficamten programme targets the same broader cardiac myosin inhibitor category. Cytokinetics shares recently traded at $77.13, with a market capitalisation of about $9.5 billion. The stock declined about 4.1% in the latest session, showing that investors remain sensitive to regulatory, commercial and competitive developments even after meaningful clinical progress.

Cytokinetics has already advanced aficamten significantly, including approvals in obstructive HCM and positive data in non-obstructive HCM. That places pressure on Braveheart Bio to show why BHB-1893 can be more than another entrant behind existing leaders.

Braveheart Bio’s advantage is focus and speed. A young company can make clinical development decisions quickly and build its organisation around one disease area. Its disadvantage is that it lacks commercial infrastructure, long-term safety data, payer relationships and late-stage trial experience at scale.

The IPO valuation must therefore balance category validation against competitive lag. Public investors may accept that Braveheart Bio is entering a valuable market, but they will still ask whether the company can earn meaningful share once larger and more advanced rivals are already moving.

Why is non-obstructive HCM central to Braveheart Bio’s investor story?

Non-obstructive hypertrophic cardiomyopathy is central because it represents a larger and more difficult commercial opportunity. Patients with non-obstructive disease can still experience symptoms, reduced functional capacity and disease progression, but treatment options have historically been limited.

Bristol Myers Squibb’s Camzyos has not established the same position in non-obstructive disease as in obstructive HCM. Cytokinetics has reported positive topline results in non-obstructive HCM, making the field more competitive but also more validated.

Braveheart Bio’s Phase 2 data with HRS-1893 in non-obstructive HCM are therefore central to the IPO pitch. If BHB-1893 can show strong benefit in this population, the company could position itself not only as another obstructive HCM contender but as a competitor in a market where the standard of care is still evolving.

That is important because the first drug in a category does not always capture every patient segment. Later entrants can succeed if they offer better dosing, fewer safety concerns, improved tolerability, broader use or stronger data in a subset of patients.

However, non-obstructive HCM development is not easy. Clinical endpoints, patient selection, trial duration and regulatory expectations can be more complex than in obstructive disease. Investors must watch whether Phase 2 signals translate into robust Phase 3 outcomes.

The IPO proceeds will likely fund the expensive part of that journey. Early proof is useful, but pivotal trials decide whether a biotech becomes a commercial company or returns to investors for another round of risk capital.

What does the Hengrui Pharma relationship bring to Braveheart Bio?

Braveheart Bio’s relationship with Hengrui Pharma is important because BHB-1893 is also known as HRS-1893, reflecting its origin and development connection with Hengrui. Hengrui and Braveheart Bio announced positive Phase 2 results in non-obstructive HCM in May 2026, giving the programme clinical visibility before the IPO.

A partnership of this kind can be valuable for a young biotech. Hengrui brings drug-development capability, chemistry experience and clinical data generation, while Braveheart Bio focuses on building a U.S.-listed company around global development and commercialisation potential.

The China-linked development pathway may also help if data are generated across patient populations and clinical systems. Global cardiovascular drug development increasingly benefits from international trial experience, provided data quality, regulatory acceptance and trial conduct meet major-market standards.

However, cross-border pharmaceutical relationships also require careful management. Investors will want clarity on rights, milestones, royalties, manufacturing obligations, data ownership, regulatory responsibilities and economics across regions.

The S-1 and subsequent IPO disclosures will be important because public investors need to understand exactly how much value Braveheart Bio controls. A promising asset can still create valuation uncertainty if licensing economics or territorial rights are complex.

The partnership strengthens the clinical story, but it also makes contract clarity essential. Investors are not only buying a molecule. They are buying the economics attached to that molecule.

Can a two-year-old biotech justify a valuation of up to $1.2 billion?

Braveheart Bio’s age is one of the most striking features of the IPO. Founded in 2024, the company is seeking a valuation of up to $1.2 billion only two years later.

That pace is unusual but not impossible in modern biotech. A company can move quickly when it starts with a licensed or partnered clinical asset, strong venture backers, experienced leadership and a defined development path. Investors may value the asset and clinical opportunity more than the corporate age.

The company’s $185 million Series A also provided a substantial early capital base. Backers such as Andreessen Horowitz, Forbion and OrbiMed helped establish credibility before the IPO filing.

Still, a $1.2 billion valuation requires confidence that BHB-1893 can reach later-stage development, compete with existing therapies and support a meaningful commercial opportunity. Public investors may compare the valuation with Cytokinetics’ much larger public market value, but Cytokinetics is substantially further along commercially and clinically.

The valuation also must account for future dilution. Biotech companies often need additional capital before approval and commercial launch, especially when running global Phase 3 trials. Even a successful IPO may not be the final financing event.

The strongest argument for Braveheart Bio is that HCM is a validated, high-value category and that BHB-1893 may address important unmet need. The weakest argument is that investors are being asked to pay a premium before pivotal data, regulatory approval or commercial infrastructure.

How does the biotech IPO backdrop affect Braveheart Bio’s timing?

The biotech IPO backdrop has improved in 2026, but it remains selective. Investors are no longer funding every early-stage platform story. They are showing more interest in companies with clearer clinical assets, defined indications and financing needs tied to identifiable milestones.

Braveheart Bio fits that preference better than a preclinical platform company. It has a lead drug candidate, human data, a recognised mechanism and a disease area with established commercial precedent.

At the same time, biotech investors have become more valuation-sensitive. Many companies that went public during earlier biotech windows struggled after clinical delays, weak data or financing pressure. Public buyers now demand cleaner stories, better capital discipline and more realistic pricing.

Braveheart Bio’s IPO will therefore test whether a focused cardiovascular biotech can attract demand at a unicorn valuation. Cardiovascular disease is attractive because of large patient populations and established prescribing infrastructure, but development can be expensive and outcomes must be clinically convincing.

The cornerstone interest from Fidelity may help. So does the involvement of healthcare-focused underwriters. But the final outcome will still depend on market appetite at pricing.

If Braveheart Bio prices well and trades constructively, it could encourage other clinical-stage cardiovascular and specialty-pharma companies to move toward IPOs. If it struggles, it may reinforce that biotech markets are open only for the strongest or most conservatively priced names.

What risks should investors watch before and after the IPO?

The first risk is clinical execution. BHB-1893 must move from Phase 2 signals into larger, well-controlled trials that can satisfy regulators and physicians.

The second risk is safety. Cardiac myosin inhibitors require careful evaluation because excessive reduction in cardiac contractility can create patient risk. Monitoring requirements can also affect adoption.

The third risk is competition. Bristol Myers Squibb and Cytokinetics have already established strong positions in the cardiac myosin inhibitor category.

The fourth risk is regulatory uncertainty. Braveheart Bio must align trial design, endpoints, patient selection and safety monitoring with U.S. and international regulatory expectations.

The fifth risk is commercial differentiation. Even if approved, BHB-1893 must offer a reason for physicians and payers to choose it over existing or emerging alternatives.

The sixth risk is financing. The IPO proceeds may fund major development milestones, but additional capital may be required before approval or commercial launch.

The seventh risk is licensing economics. Investors need clarity on Braveheart Bio’s rights and obligations connected to Hengrui Pharma and HRS-1893.

The eighth risk is valuation. A $1.2 billion ceiling valuation prices in significant future success before pivotal data are available.

What should investors watch after Braveheart Bio begins trading?

The first milestone is IPO pricing. Pricing at the top of the $15 to $17 range would show stronger investor demand, while pricing below range would indicate valuation resistance.

The second milestone is Fidelity’s actual allocation. The indicated $75 million interest is meaningful, but investors will watch whether the cornerstone demand materialises as expected.

The third milestone is Nasdaq trading performance under BRVE. Early trading will show whether investors see Braveheart Bio as a scarce HCM opportunity or another risky clinical-stage biotech.

The fourth milestone is Phase 3 planning. Details around trial size, endpoints, geography, comparator strategy and timing will determine how investors model the development path.

The fifth milestone is additional data in obstructive and non-obstructive HCM. Differentiation against Camzyos and Myqorzo will require strong evidence, not only mechanism-level validation.

The sixth milestone is cash runway. Investors should track how far IPO proceeds can fund development before another financing becomes necessary.

The seventh milestone is partnership clarity. Any additional disclosure or amendments around Hengrui economics could affect valuation.

Braveheart Bio’s IPO is a useful test for the 2026 biotech window. It has a validated mechanism, respected backers, a clear disease focus and cornerstone interest. It also has all the classic risks of a young clinical-stage biotech entering public markets before pivotal data. The listing will show whether investors are ready to underwrite the next wave of HCM competition, or whether they want Braveheart Bio to prove more before rewarding it with a billion-dollar valuation.

Key takeaways on what Braveheart Bio’s IPO means for biotech investors

• Braveheart Bio is targeting a valuation of up to $1.2 billion in its planned U.S. IPO.
• The company plans to offer 18.8 million shares at $15 to $17 each.
• At the top end of the range, Braveheart Bio could raise about $318.8 million.
• The company intends to list on the Nasdaq Global Market under the ticker symbol BRVE.
• Fidelity Management & Research has indicated interest in buying up to $75 million of shares at the IPO price.
• Braveheart Bio’s lead programme, BHB-1893, also known as HRS-1893, is an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.
• The company was founded in 2024 and has raised about $185 million in Series A funding.
• Backers include Andreessen Horowitz, Forbion and OrbiMed.
• The HCM market is increasingly competitive, with Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo already shaping physician expectations.
• The biggest risks are clinical execution, safety monitoring, competition, financing needs, licensing economics and valuation pressure.